TAK - Takeda Canadian Blood Services ink pact for immunodeficiency disease drugs

2023-04-20 07:26:38 ET

• Takeda Canada said it signed a three-year agreement with Canadian Blood Services (CBS) for immunoglobulin therapies to treat immunodeficiency diseases.
• The Takeda Pharmaceutical's ( NYSE: TAK ) Canadian unit's agreement includes Gammagard Liquid, Gammagard S/D and Cuvitru, resulting from CBS's request for proposal for immunoglobulin therapy within its formulary mix.
• The company noted that the agreement is the second consecutive time it has received a significant award for these products with the option for two one-year extensions.
• "This is positive news for Canadians with immune deficiencies that rely upon innovative therapies to help protect against infection," said Rute Fernandes, General Manager, Takeda in Canada.

For further details see: